<DOC>
	<DOCNO>NCT02494830</DOCNO>
	<brief_summary>This study design descriptive pharmacokinetic characterization ketamine norketamine serum , urine feces oral single dose administration new develop prolonged release tablet formulation contain 10 , 20 , 40 80 mg ketamine fast condition descriptive pharmacokinetic characterization ketamine norketamine serum , urine feces intravenous single dose administration 5 mg ketamine solution infusion within 30 min</brief_summary>
	<brief_title>Single Dose Administration Ketamine 10 , 20 , 40 80 mg 5 mg Solution Infusion 15 Healthy Subjects</brief_title>
	<detailed_description>Ketamine , cyclohexanone derivative , non-barbiturate anesthetic agent available clinical practice 40 year . Ketamine first synthesize 1962 patent Belgium 1963 . Ketamine , potent non-competitive N-methyl-D-aspartate ( NMDA ) receptor antagonist , recognize unique therapeutic value human veterinary medicine anesthetic analgesic property . Ketamine consider one World Health Organisation ( WHO ) essential drug management refractory pain . Ketamine widely use induction maintenance general anesthesia , usually combination sedative require muscle relaxant . When use intravenous ( i.v . ) intra-muscular ( i.m . ) injection , ketamine best suit short procedure . With additional dos , i.v . infusion , ketamine use long procedure . Due pharmacodynamic property , important clinical application mainly brief diagnostic one surgical procedure paediatric patient ambulatory anesthesia , treatment burn patient , obstetrics , induction maintenance anesthesia trauma victim , hypovolemic patient , patient septic cardiogenic shock , patient pulmonary disease . Other us include sedation intensive care set , analgesia particularly emergency medicine well treatment bronchospasm / asthma . However , use ketamine human EU restrict special indication , due occurrence emergence reaction . Outside EU , ease use give ketamine major advantage difficult circumstance ( develop country remote area ) . For therapeutic purpose , ketamine usually administer intravenously ( i.v . ) intramuscularly ( i.m. ) . Its hydrochloride salt market many brand name Ketanest , Ketalar , Ketaset . Ketamine chiral compound . While marketed ketamine preparation racemic mixture R- ( - ) -ketamine S- ( + ) -ketamine ( 1:1 ) , formulation contain enantiomer S- ( + ) -ketamine also commercially available ( e.g . Ketanest® S , Pfizer Pharma GmbH ) . S- ( + ) -ketamine approximately four time potent R- ( - ) -ketamine twice potent racemic mixture . It well-known ketamine exerts analgesic effect subanesthetic dos . Therefore , past 15-20 year , ketamine use analgesic wide range pain setting , include acute ( e.g . post-operative pain , pain dental procedure ) chronic pain ( e.g . central peripheral neuropathic pain , cancer pain ) condition . Although drug approve intramuscular injection intravenous injection infusion , ketamine frequently use via route administration , subcutaneous ( s.c. ) injection infusion , rectal , oral , intranasal , transdermal ( patch ) , intrathecal epidural administration . Considering oral formulation approve , market solution injection/infusion extemporaneous preparation use clinical study investigate efficacy orally administer ketamine . For clinical ( off-label ) use , solution injection/infusion generally employ oral treatment .</detailed_description>
	<mesh_term>Ketamine</mesh_term>
	<criteria>age : 18 45 year sex : male female ethnic origin : Caucasian body mass index : &gt; 18.5 kg/m² &lt; 30 kg/m² good health evidence result clinical examination , ECG , laboratory checkup , judge clinical investigator differ clinically relevant way normal state heart frequency 50 90 bpm blood pressure 140 100 systolic 90 60 diastolic write informed consent hepatic renal disease and/or pathological finding , might interfere pharmacokinetics study medication exist cardiovascular haematological disease and/or pathological finding , might interfere drug 's safety , tolerability and/or pharmacokinetics ( e.g . tachycardia &gt; 90 bpm , bradycardia &lt; 50 bpm , ischemic heart disease like angina pectoris instabilis myocardial infarction last 6 month , hypertension &gt; 140/90 mm Hg ) gastrointestinal disease and/or pathological finding ( e.g . stenosis ) , might interfere pharmacokinetics study medication hypersensitivity active ingredient ketamine excipients ( pre ) eclampsia poor untreated hyperthyreosis increase intracranial pressure glaucoma perforate eye injury drug alcohol dependence positive drug alcohol screen smoker 10 cigarette ( equivalent ) per day positive result HIV , HBV HCV screen volunteer , diet , could affect pharmacokinetics drug heavy tea coffee drinker ( 1L per day ) lactation , pregnancy test positive perform woman childbearing age without safe contraception , describe page 18 , ch . 7.4.1 . ( Note Guidance Nonclinical Safety Studies Conduct Human Clinical Trials Pharmaceutical ( CPMP/ICH/286/95 modification ) ) volunteer , suspect know , follow instruction clinical investigator volunteer , unable understand write verbal instruction , particular regard risk inconvenience , expose , result participation study volunteer , liable orthostatic dysregulation , fainting , blackouts participation clinical trial last 3 month prior start study le 14 day last acute disease le 3 month last blood donation intake thyroid hormone sympathomimetics medication within 4 week prior intend first administration study medication , might influence function gastrointestinal tract ( e.g . laxative , metoclopramide , loperamide , antacid , H2receptor antagonists , proton pump inhibitor , anticholinergic ) medication within two week prior first administration study medication , least 10time halflive respective drug ( except oral contraceptive ) intake grapefruit contain food beverage within 14 day prior administration study medication intake poppy seed contain food beverage within 14 day prior administration study medication know allergic reaction active ingredient use constituent study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Anesthetic Drugs</keyword>
</DOC>